DexCom, Inc. USDC – Southern District of New York november 6, 2025 CLASS PERIOD: july 26, 2024 – september 17, 2025LEAD PLAINTIFF DEADLINE: december 26, 2025 Please complete the form below to contact Kaplan Fox regarding the DexCom Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Principle Contacts Pamela MayerPMayer@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox Alerts Investors of DexCom, Inc. (DXCM) to a Securities Class Action Deadline on December 26, 2025 Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) on behalf of investors that purchased or otherwise acquired DexCom securities between July 26, 2024 and September 17, 2025 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you purchased DexCom securities during the Class Period and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than December 26, 2025 to serve as a lead plaintiff for the purported class. If you have losses, we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. The complaint alleges that the G7 is DexCom’s flagship product and, accordingly, the commercial success of the G7 is of paramount importance to both investors and Defendants. Further, according to the complaint, at all relevant times, Defendants consistently touted the accuracy, reliability, and functionality of the G7, as well as their purported enhancements to the device and the ramping up of its manufacturing facilities. Additionally, according to the complaint the truth began to emerge on March 7, 2025 when DexCom disclosed in a filing with the United States Securities and Exchange Commission that three days earlier, it had received a warning letter from the United States Food and Drug Administration (the “FDA”) related to concerns about manufacturing processes and quality management systems at certain of the Company’s facilities. On this news, DexCom’s stock price fell $7.12 per share, or 9.15%, to close at$70.72 per share on March 10, 2025. The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (i) (i) DexCom had made material design changes to the G6 and G7 unauthorized by the FDA; (ii) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) accordingly, Defendants’ purported enhancements to the G7, as well as the device’s reliability, accuracy, and functionality, were overstated; (iv) Defendants downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; (v) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm; and (vi) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times. WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT:Pamela A. MayerKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(646) 315-9003pmayer@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704lking@kaplanfox.com The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. Any information you submit will be maintained as confidential. If Kaplan Fox, in its sole discretion, believes that you might be an appropriate client, Kaplan Fox will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases. Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us DexCom, Inc. See the Case Stride, Inc. See the Case Organon & Co See the Case Marex Group plc See the Case CarMax, Inc. See the Case Fluor Corporation See the Case KBR, Inc. See the Case RCI Hospitality Holdings, Inc. See the Case Barnes & Noble Education, Inc. See the Case Dow, Inc. See the Case Semler Scientific, Inc. See the Case LifeMD, Inc. See the Case
